Related Experiment Video
Updated: May 30, 2026
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
An oestrogen receptor β-selective agonist exerts anti-neoplastic effects in experimental intrahepatic
Marco Marzioni1, Alessia Torrice, Stefania Saccomanno
1Department of Gastroenterology, Università Politecnica delle Marche, Ancona, Italy.
Background:
Cholangiocarcinoma cells over-express oestrogen receptor-β, which displays anti-proliferative and pro-apoptotic effects.
Aim:
To evaluate the effects of a newly developed and highly selective oestrogen receptor-β agonist (KB9520) on experimental intrahepatic cholangiocarcinoma.
Methods:
In vitro, the effects of KB9520 on apoptosis and proliferation of HuH-28 cells, HuH-28 cells with selective oestrogen receptor-β silencing (by small interfering RNA), HepG2 cells (oestrogen receptor-α and oestrogen receptor-β negative) and HepER3 cells (HepG2 cells transformed to stably express oestrogen receptor-α) were evaluated. In vivo, the effects of KB9520 on experimental intrahepatic cholangiocarcinoma, induced by thioacetamide administration were tested.
Results:
In vitro, KB9520 induced apoptosis and inhibited proliferation of HuH-28 cells. KB9520 effects were absent in cells lacking oestrogen receptor-α and β (HepG2) and in cells expressing only oestrogen receptor-α (HepER3); its pro-apoptotic effect was impaired in cells where oestrogen receptor-β expression was decreased by specific small interfering RNA. In vivo, KB9520 inhibited experimental intrahepatic cholangiocarcinoma development in thioacetamide-treated rats and promoted tumour regression in rats where tumour was already established. In treated animals, tumour areas showed reduced proliferation but increased apoptosis.
Conclusions:
KB9520 induced apoptosis in cholangiocarcinoma by selectively acting on oestrogen receptor-β, suggesting that oestrogen receptor-β selective agonists may be a novel and effective therapeutic option for the medical treatment of intrahepatic cholangiocarcinoma.
Insights
A new drug, KB9520, selectively targets oestrogen receptor-β to inhibit cholangiocarcinoma cell growth and promote apoptosis. This suggests oestrogen receptor-β agonists are a promising new treatment for intrahepatic cholangiocarcinoma.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Cholangiocarcinoma (CCA) cells overexpress oestrogen receptor-β (ERβ).
- ERβ activation exhibits anti-proliferative and pro-apoptotic effects in cancer cells.
- Targeting ERβ represents a potential therapeutic strategy for CCA.
Purpose of the Study:
- To evaluate the efficacy of a novel, selective ERβ agonist, KB9520.
- To assess KB9520's effects on experimental intrahepatic cholangiocarcinoma (iCCA) models.
Main Methods:
- In vitro studies utilized various cell lines (HuH-28, HepG2, HepER3) with differential ER expression, including ERβ silencing.
- In vivo studies involved a thioacetamide-induced rat model of iCCA.
- KB9520's impact on cell proliferation, apoptosis, and tumor growth/regression was measured.
Main Results:
- KB9520 induced apoptosis and inhibited proliferation in ERβ-positive HuH-28 cells.
- KB9520's effects were absent in ER-negative (HepG2) and ERα-only (HepER3) cells.
- In vivo, KB9520 inhibited iCCA development and promoted tumor regression, with reduced proliferation and increased apoptosis observed in tumors.
Conclusions:
- KB9520 demonstrates potent anti-cancer effects in iCCA models by selectively activating ERβ.
- Selective ERβ agonists, like KB9520, represent a novel therapeutic avenue for intrahepatic cholangiocarcinoma.
- Further investigation into ERβ-targeted therapies for CCA is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists